Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.
Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.
We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.
Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.
Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.
Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.
Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.
Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.